Design Therapeutics, Inc.: financing cash flow
Financing cash flow for Design Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Design Therapeutics, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 25,738,000 | USD | 2026-03-09 | 10-K · 0001193125-26-098491 |
| 2024-01-01 | 2024-12-31 | 513,000 | USD | 2026-03-09 | 10-K · 0001193125-26-098491 |
| 2023-01-01 | 2023-12-31 | 724,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035910 |
| 2022-01-01 | 2022-12-31 | 235,000 | USD | 2024-03-19 | 10-K · 0000950170-24-033492 |
| 2021-01-01 | 2021-12-31 | 379,211,000 | USD | 2023-03-14 | 10-K · 0000950170-23-007869 |
| 2020-01-01 | 2020-12-31 | 44,532,000 | USD | 2022-03-10 | 10-K · 0000950170-22-003369 |
Related financial histories
- Design Therapeutics, Inc.: total assets
- Design Therapeutics, Inc.: total liabilities
- Design Therapeutics, Inc.: stockholders equity
- Design Therapeutics, Inc.: cash and cash equivalents
- Design Therapeutics, Inc.: net income or loss
- Design Therapeutics, Inc.: operating cash flow
- Design Therapeutics, Inc.: capital expenditure payments
- Design Therapeutics, Inc.: investing cash flow
- Design Therapeutics, Inc.: retained earnings or deficit
- Design Therapeutics, Inc.: basic weighted-average shares
- Design Therapeutics, Inc.: diluted weighted-average shares
- Design Therapeutics, Inc.: basic earnings per share
- Design Therapeutics, Inc.: diluted earnings per share
- Design Therapeutics, Inc.: net property, plant and equipment
- Design Therapeutics, Inc.: share-based compensation expense
- Design Therapeutics, Inc.: operating income or loss
- Design Therapeutics, Inc.: current assets
- Design Therapeutics, Inc.: current liabilities
- Design Therapeutics, Inc.: current accounts payable
- Design Therapeutics, Inc.: operating expenses
- Design Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Design Therapeutics, Inc. / CIK 0001807120
- Captured
- 2026-09-21T17:28:13.985Z
- SEC response SHA-256
17e755cf4dc3ba9be3535a65aea0e4914677f8625c9662e22a7556c5fd4c086a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001807120.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))